U18666A | 2855-62-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: U18666A
• 英文别名: 3-β-[2-(diethylamino)ethoxy]androst-5-en-17-one；3beta-(beta-Dimethylaminoethoxy)androst-5-en-17-one；3beta-(2-(Diethylamino)ethoxy)androst-5-en-17-one；(3S,8R,9S,10R,13S,14S)-3-[2-(diethylamino)ethoxy]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one
• CAS: 2855-62-1
• 化学式: C₂₅H₄₁NO₂
• 分子量: 387.606
• InChiKey: DMZCCFMMPHJWQY-BKWLFHPQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  去氢表雄酮 、 N,N-二乙基氯乙胺 生成 U18666A
  参考文献：
  名称：

  CAVALLINI; MASSARANI, Il Farmaco, 1951, vol. 6, # 3, p. 287 - 290

  摘要：

  DOI：

文献信息

• Methods for Determining the Oncogenic Condition of Cell, Uses Thereof, and Methods for Treating Cancer
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

  公开号：US20170176446A1

  公开（公告）日：2017-06-22

  The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer.

  这项发明涉及检测细胞的致癌状态的方法，包括测量所述细胞中OCDO化合物的数量的步骤，以及其用途。该发明还涉及用于治疗癌症方法中使用的OCDO抑制剂。
• METHODS FOR DETERMINING THE ONCOGENIC CONDITION OF CELL, USES THEREOF, AND METHODS FOR TREATING CANCER
  申请人：De Medina Philippe

  公开号：US20120100124A1

  公开（公告）日：2012-04-26

  The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer.

  本发明涉及用于检测细胞的致癌状态的方法，其中包括测量所述细胞中OCDO化合物的量的步骤，并涉及其用途。本发明还涉及用于治疗癌症的OCDO抑制剂的使用方法。
• [EN] INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER<br/>[FR] INDUCTION DU RÉCEPTEUR BÊTA DES OESTROGÈNES PAR DES INHIBITEURS DE LA BIOSYNTHÈSE DU CHOLESTÉROL ET MÉTHODES DE TRAITEMENT DU CANCER
  申请人：UNIV MISSOURI

  公开号：WO2014004854A1

  公开（公告）日：2014-01-03

  Disclosed herein are methods and compositions related to the discovery that cholesterol inhibitors induce the anti-proliferative protein, estrogen receptor beta (ERβ), in both ERα- positive and ERα-negative breast cancer cell lines, including triple negative cells.

  本文揭示了与发现胆固醇抑制剂在ERα阳性和ERα阴性乳腺癌细胞系，包括三阴性细胞中诱导抗增殖蛋白雌激素受体β（ERβ）相关的方法和组合物。
• OXIDOSQUALENE CYCLASE AS A PROTEIN TARGET FOR ANTICANCER THERAPEUTICS
  申请人：Hyder Salman M.

  公开号：US20140005187A1

  公开（公告）日：2014-01-02

  The present invention identifies the cholesterol biosynthetic pathway, including the enzyme oxidosqualene cyclase, as new protein targets for anti-tumor therapeutics. The present invention further provides a class of oxidosqualene cyclase inhibitors containing a tertiary amine linked with aromatic ring structures, as a new class of anticancer agents. Compounds disclosed herein have been tested in 19 cell lines including breast cancer, prostate cancer, lung cancer (including drug-resistant lung cancer H69AR), colon cancer, ovarian cancer (including drug-resistant OVCAR-3), and pancreatic cancer cells, as wells as in human breast and prostate xenograft tumor growth in nude mice, and have been shown to be active.

  本发明确定了胆固醇生物合成途径，包括酶氧化齐墩果烷环化酶，作为抗肿瘤治疗的新蛋白靶点。本发明还提供了一类含有与芳香环结构相连的三级胺的氧化齐墩果烷环化酶抑制剂，作为一类新的抗癌剂。本文所披露的化合物已经在19种细胞系中进行了测试，包括乳腺癌、前列腺癌、肺癌（包括耐药性肺癌H69AR）、结肠癌、卵巢癌（包括耐药性OVCAR-3）和胰腺癌细胞，以及在裸鼠的人类乳腺和前列腺异种移植肿瘤生长中显示出活性。
• Experimental models of age-related macular degeneration and related retinal disorders
  申请人：Centre National de la Recherche Scientifique- CNRS

  公开号：EP2161330A1

  公开（公告）日：2010-03-10

  The present invention relates to experimental models of age-related macular degeneration (AMD) and related retinal disorders and to screening methods using these models for detecting molecule candidates for the treatment of AMD. In particular, the present invention relates to the use of an animal or a cell that is deficient in functional Niemann Pick type C-related protein as experimental model of AMD and vision disorders resulting from AMD. The present invention founds industrial applications for preclinical research and development on age-related macular degeneration and similar diseases. Examples of potential industrial application are in companies that have a preclinical R&D program in retinal diseases, particularly in AMD.

  本发明涉及老年性黄斑变性（AMD）及相关视网膜疾病的实验模型，以及利用这些模型检测治疗AMD候选分子的筛选方法。特别是，本发明涉及使用缺乏功能性尼曼皮克 C 型相关蛋白的动物或细胞作为 AMD 和 AMD 导致的视力障碍的实验模型。本发明可用于老年性黄斑变性和类似疾病的临床前研究和开发。潜在的工业应用实例包括在视网膜疾病，特别是老年黄斑变性方面开展临床前研发项目的公司。